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Abstract
Objective: Gengraf capsule, an AB-rated generic cyclosporine for Neoral, has been shown to be
bioequivalent in previous studies. The objective of this study was to evaluate the pharmacokinetics
and bioequivalence of Gengraf and Neoral in stable Chinese renal allograft recipients
Methods: In a prospective, open-label, two-period design study, 20 renal allograft recipients receiving
stable doses of Neoral were recruited. Subjects continued their Neoral regimen during period I
(days 1-14). They were then switched from Neoral on a milligram-for-milligram basis to Gengraf
during period II (days 15-28). Four-hour pharmacokinetic parameters (concentration before dosing
[Ctrough], maximum blood concentration [Cmax], time to maximum concentration [Tmax], and area
under the blood concentration-versus-time curve [AUC0-4]) were taken on days 1, 8, 21, and 28.
Biochemical parameters were also evaluated.
Results: There was no significant difference in the pharmacokinetics of Gengraf (Ctrough, Tmax,
Cmax, and AUC0-4) as compared with that of Neoral in stable renal transplant recipients. The
bioequivalent capsules were interchangeable with respect to Ctrough, Cmax and AUC0-4. The 90%
confidence intervals of the ratio of Ctrough, Cmax, Tmax, and AUC0-4 of Gengraf and Neoral were
0.94 to 1.21 for Ctrough, 0.97 to 1.20 for Cmax, and 0.97 to 1.20 for AUC0-4. Ctrough and C2 remained
stable throughout the study without any dosage adjustments. Gengraf was well tolerated, and
had a comparable safety profile as Neoral.
Conclusion: Gengraf are bioequivalent to Neoral. Gengraf is well tolerated and interchangeable
with Neoral in stable Chinese renal allograft recipients.
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INTRODUCTION
Cyclosporine is a lipophilic cyclic polypeptide that has
been used as first-line immunosuppressive therapy for
patients undergoing solid organ transplantation. The oil-
based formulation of the drug, Sandimmune, (Sandoz,
Basel, Switzerland) was characterized by poor and
unpredictable absorption and the need for intensive
monitoring of blood cyclosporine concentrations and
frequent dosage adjustments to obtain the desired
therapeutic level after oral administration. In the mid
1990s, however, a novel microemulsion preconcentrate,
Neoral, (Novartis, Basel, Switzerland) was introduced.
This enhanced the bioavailability of the drug and reduced
the variability in pharmacokinetic characteristics (1,2).
The introduction of Neoral has prompted much research
into therapeutic drug monitoring, with the aim of
identifying methods that predict exposure to the drug
accurately and thereby assist in the optimization of
therapeutic outcomes. This approach, termed "absorption
profiling," has the underlying rationale that the 4-hour
absorption phase following administration provides
measurements that are more informative than
cyclosporine trough level (Ctrough) monitoring in the
assessment of likely cyclosporine exposure and
subsequent clinical response (3). Achievement of AUC0-4
target levels reduced the incidence of acute rejection in
early transplant period (4). However, multiple time point
AUC0-4 sampling is not the most practical solution.
Single-time sampling of cyclosporine level at 2 hours
(C2) showed very good correlation with AUC0-4 (5).
Patient management by Neoral C2 monitoring in de novo
renal transplants resulted in a very low incidence of acute
rejection with a good safety profile (6).
In May 2000, the United States Food and Drug
Administration approved Gengraf capsules (Abbott
Laboratories, Abbott Park, US)  as AB-related
bioequivalent to Neoral cyclosporine for the prevention
of organ-graft rejection in kidney, liver, and heart
transplant recipients. Gengraf has been shown to be
bioequivalent to Neoral in stable renal allograft recipients
(7). We performed a prospective study of 20 Chinese
renal transplant recipients on Neoral maintenance
immunosuppressive therapy. The purpose of the study
was to evaluate the pharmacokinetics and to establish
bioequivalence between Gengraf and Neoral in stable
Chinese renal transplant patients.
PATIENTS AND METHODS
Study design
In January 2002, 20 renal transplant patients were
recruited for the study after obtaining informed consent
for participation. The study was approved by the Ethics
Committee of Princess Margaret Hospital. During the
screening period, study subjects were evaluated for
enrollment on the basis of a complete medical history,
physical examination, vital signs, and clinical laboratory
testing. Subjects were maintained during screening on
their usual stable oral dose of twice-daily Neoral. During
period I (days 1-14), study subjects received a 2-week
course of twice-daily Neoral cyclosporine capsules. For
the next 2-week period (period II, days 15-28), subjects
were replaced to twice-daily Gengraf cyclosporine
capsules at an equal milligram-for-milligram dose as their
usual twice-daily Neoral dose.
Inclusion and exclusion criteria
Men or non-pregnant, non-lactating women aged 18 to
65 years who had undergone renal transplant were
allowed to participate in the study. Women of
childbearing potential were required to use medically-
acceptable methods of contraception and test negative
for pregnancy at screening. Subjects were at least 3
months post renal transplant and on a stable twice-daily
dosage of Neoral cyclosporine capsules with stable
trough cyclosporine levels before the screening period.
Subjects demonstrated no gastrointestinal tract, renal or
hepatic diseases that might alter cyclosporine
metabolism. Subjects were not allowed to take any
nephrotoxic drugs or drugs known to significantly change
cyclosporine clearance during this study.
Data collection
Four-hour pharmacokinetic evaluations were obtained
on days 1 and 8 (period I, Neoral), days 21 and 28 (period
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RESULTS
Demographic data
Twenty subjects were recruited for the study and they
all completed the study. Demographic characteristics for
the study subjects were shown listed in Table 1. The
average dose of Neoral was 210 ± 49.5 mg/day. They
were maintained on their usual stable dosage of twice-
daily Neoral during the first 2 weeks. Afterwards, they
were switched from Neoral on a milligram-for-milligram
basis to twice-daily Gengraf.
After switching from Neoral to Gengraf, the following
pharmacokinetic parameters were observed. The Ctrough
increased from 127 ± 50.1 µg/L to 142.6 ± 49.1 µg/L
(p=0.052). AUC0-4 increased from 2421 ± 722 µg x hr/L
to 2637 ± 846 µg x hr/L (p=0.38). Tmax was delayed from
1.53 ± 0.72 hours to 1.8 ± 0.9 hours (p=0.51) (Table 2).
Concerning the bioequivalence of two formulations of
cyclosporine, the point estimates of relative bio-
availability for Ctrough, Cmax and AUC0-4 were 1.12, 1.09,
and 1.09, respectively. The 90% confidence intervals of
the test reference geometric mean ratio were within the
80% to 125% bioequivalence range. Thus the
II, Gengraf). Venous whole-blood samples were collected
by venipuncture at pre-doses (0 hour) and then at 1, 1.5,
2 and 4 hours after morning dose of cyclosporine.
Cyclosporine blood concentrations were measured using
a validated enzyme multiplied immunoassay (EMIT
assay, Syva Company, Cupertino, US).
Serum biochemical testing, which included electrolytes,
blood urea nitrogen, creatinine, total bilirubin, alkaline
phosphatase, alanine aminotransferase, total protein, and
albumin was performed on days 1, 8, 21 and 28. In
addition, a complete blood count with differential was
collected on these days.
Statistical methods
Biochemical and pharmacokinetic parameters of
cyclosporine were compared using paired t test. The
concentration before dosing (Ctrough), the maximum blood
concentration (Cmax), and the time to maximum
concentration (Tmax) were taken directly from blood
concentration measurements. The area under the blood
concentration-versus-time curve from time 0 to 4 hours
after drug administration (AUC0-4) was calculated using
the linear trapezoidal method.
Before analysis, values for Ctrough, Cmax, and AUC0-4 were
log transformed. The two one-sided hypotheses were
tested at the 5% level for Ctrough, Cmax, and AUC0-4 by
constructing 90% confidence intervals for the ratio of
the geometric test and reference means. Bioequivalence
with respect to a specific variable was established if the
90% confidence interval of the ratio means fell within
the range of 80% to 125% (8).
Intraindividual pharmacokinetic variability was
expressed as the percent coefficient of variation
calculated as MSE x 100/mean, where MSE is the
mean squared error of the replicated pharmacokinetic
values. Intraindividual variations were compared by F
tests. Statistical hypotheses were tested at the 0.05 level
of significance.
Number of patients 20
Gender
   Male 12
   Female 8
Age, years 48.4 ±10.7
Body weight, kg* 65.9 ± 11.2
Time since transplant, months* 7.2 ± 4.8
Dose of cyclosporine, mg/d* 210 ± 49.5
Immunosuppressive regimen*
   Cyclosporine/prednisolone 6
   Cyclosporine/prednisolone/MMF 9
   Cyclosporine/prednisolone/azathioprine 5
MMF = mycophenolate mofetil
*Data were presented as arithmetic mean ± standard deviation.
Table 1. Demographic data.
Pharmacokinetic parameters Gengraf (n = 20)* Neoral (n = 20)* Ratio† 90% CI‡ p value
Ctrough, µg/L 142.6 ± 49.1 127 ± 50.1 1.12 0.94-1.21 0.052
Cmax, µg/L 1101.9 ± 425.6 1007 ± 358 1.09 0.97-1.20 0.33
AUC0-4, µg x hr/L 2637 ± 846 2421 ± 722 1.09 0.97-1.20 0.38
C2, µg/L 913.3 ± 359.7 728 ± 220 0.09
Tmax, hour 1.8 ± 0.9 1.53 ± 0.72 0.051
CI = confidence interval
*Data were presented as arithmetic mean ± standard deviation.
†Ratio = the ratio of Ctrough, Cmax and AUC0-4 of Gengraf and Neoral.
‡90% confidence intervals for the ratio of the above pharmacokinetic parameters. Bioequivalence with respect to a specific parameter was
established if the 90% CI of the ratio means fell within the range of 80% to 125%.
Table 2. Pharmacokinetics and bioequivalence analysis of Gengraf and Neoral in stable renal allograft recipients.
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bioequivalence between Neoral  and Gengraf
cyclosporine capsules was demonstrated (Table 2). The
intraindividual (within subject) variability of Ctrough of
Neoral and Gengraf, as measured by the coefficients of
variation, were 18% versus 20% (p=0.395)
Safety and tolerability
No dosage adjustments of cyclosporine were required
for any subject during study period. No graft rejection
or serious adverse event occurred during the study.
Evaluation of laboratory parameters, vital signs, and
physical findings demonstrated that no clinically
significant changes from baseline occurred during the
study for any of these parameters. Serum creatinine was
120.4 ± 41.3 µmol/L in Neoral group as compared with
118.5 ± 43.1 µmol/L in Gengraf group (p=0.15).
DISCUSSION
The introduction of cyclosporine microemulsion Neoral
in renal allograft recipients has enhanced the
bioavailability of cyclosporine and reduced the
absorption variability (1). Unpredictable absorption of
Sandimmune is a common problem encountered in the
clinical management of patients with cyclosporine (9).
Development of acute or chronic rejection may be
associated with the variable absorption of cyclosporine
(10). Achievement of Neoral AUC0-4 target levels, 4400
to 5500 µg x hr/L, reduces acute rejection in early
transplant period (6). C2 has been shown to have very
good correlation with AUC0-4 (5). Therapeutic drug
monitoring using C2 is useful and practical in the patient
management.
In our study, the bioequivalence between Gengraf and
Neoral is established. However, Gengraf Ctrough, Cmax and
AUC0-4 are consistently higher than that of Neoral after
conversion although not statistically significant. No
dosage adjustment is required during the study period.
A larger scale study with longer duration of follow-up is
useful to confirm this. The coefficients of variation of
Gengraf and Neoral are 20% and 18%, respectively. The
fluctuation of Gengraf cyclosporine level is comparable
to that of Neoral. There is no acute rejection documented.
In view of the small number of patients involved, larger
scale studies in Chinese populations should be conducted
over a longer duration to assess the pharmacokinetics
and clinical outcomes of Gengraf, including patient and
graft survival rate, in de novo, and stable renal transplant
recipients
CONCLUSION
This study demonstrates that Gengraf is bioequivalent
to Neoral in a Chinese population. They can be converted
from Neoral to Gengraf on a milligram-for-milligram
basis without any dosage adjustments. There is no acute
rejection or serious adverse side effects. Gengraf is well
tolerated and has a comparable safety profile as Neoral.
The availability of bioequivalent and well-tolerated
generic formulations provides significant cost savings
in allograft recipients receiving immunosuppressive
agents.
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